Transition metal complexes with thiosemicarbazide-based ligands. Part 61. Comparative analysis of structural properties of the pyridoxal thiosemicarbazone ligands. Crystal structure of PLTSC·HCl·2H2O and its complex [Fe(PLTSC)Cl2(H2O)]Cl

被引:0
作者
Sonja A. Ivković
Ljiljana S. Vojinović-Ješić
Vukadin M. Leovac
Marko V. Rodić
Sladjana B. Novaković
Goran A. Bogdanović
机构
[1] University EDUCONS,Faculty of Environmental Protection
[2] University of Novi Sad,Faculty of Sciences
[3] University of Belgrade,Vinča Institute of Nuclear Sciences
来源
Structural Chemistry | 2015年 / 26卷
关键词
Pyridoxal thiosemicarbazone; Fe(III) complex; Crystal structures; Comparative study;
D O I
暂无
中图分类号
学科分类号
摘要
A novel pyridoxal thiosemicarbazone (PLTSC) compound, exhibiting ligating properties, of the formula PLTSC·HCl·2H2O (1) was synthesized and characterized by X-ray analysis. The PLTSC ligand 1 displays significantly different conformation in comparison to the five previously reported compounds of this type. The structural properties of six PLTSC ligands in different conformations were compared in order to establish the structural differences and understand the factors that facilitate particular conformations. The analysis indicated great structural flexibility of the PLTSC ligands. The PLTSC ligand 1 is essentially a planar molecule with the r.m.s deviation of all non-H atoms equal to 0.06 Å. Consequently, the molecules of 1 form a layered three-dimensional structure which is stabilized by a variety of hydrogen bonds: O–H⋯O, O–H⋯N, O–H⋯Cl, O–H⋯S, N–H⋯O, N–H⋯N, N–H⋯Cl, N–H⋯S. In addition, the crystal structure of the Fe(III) complex with the ligand 1 of the formula [Fe(PLTSC)Cl2(H2O)]Cl was resolved by single-crystal X-ray analysis and structural properties of this octahedral complex were discussed and compared to those of uncoordinated PLTSC ligand.
引用
收藏
页码:269 / 277
页数:8
相关论文
共 137 条
[1]  
Beraldo H(2004)undefined Mini Rev Med Chem 4 31-39
[2]  
Gambino D(2009)undefined J Med Chem 52 5271-5294
[3]  
Yu Y(2005)undefined Pharmacol Rev 57 547-583
[4]  
Kalinowski DS(2000)undefined J Coord Chem Rev 209 197-261
[5]  
Kovacevic Z(2009)undefined J Coord Chem Rev 253 977-1055
[6]  
Siafakas AR(2010)undefined Dalton Trans 39 1643-1651
[7]  
Jansson PJ(2005)undefined Antivir Chem Chemother 16 155-168
[8]  
Stefani C(2013)undefined Recent Pat Anticancer Drug Discov 8 168-182
[9]  
Lovejoy DB(2005)undefined J Serb Chem Soc 70 393-422
[10]  
Sharpe PC(2012)undefined Coord Chem Rev 256 3036-3062